AI can widen Waystar's moat, if growth holds
- Q1 2026 revenue was $313.9 million, up 22.4% year over year, helped by the Iodine acquisition.
- Net revenue retention, which shows how much existing clients spend over time, was 110.5% for the 12 months ended March 31, 2026.
- AI-powered capabilities drove roughly 40% of new bookings in Q1, a key proof point for the new product push.
- Provider Solutions now make up about 75% of revenue and carry better unit economics than Patient Payment Solutions.
- The main worry is whether organic growth can stay in double digits after Iodine and temporary tailwinds fade.
AI push meets growth test
Waystar is a healthcare payments software company. Its tools help doctors, clinics, hospitals, and health systems submit claims, fix errors, collect from patients, and get paid faster. That work is boring, but it is vital. If the software fails, cash collection slows.
The bull case got stronger after Q1 2026. Revenue reached $313.9 million, up 22.4% year over year. Net revenue retention was 110.5%, close to management's roughly 111% figure, which eased fears that existing-client growth was slipping. AI-powered capabilities drove roughly 40% of new Q1 bookings, showing that buyers are paying attention to the new product set.
The Iodine deal is the big strategic move. Iodine adds AI-powered clinical intelligence, which means software that reads medical records and spots documentation or coding problems before a claim is sent. If this works, Waystar can move from fixing payment problems after the fact to preventing them earlier in the process.
The bear case is still real. Organic revenue growth was 11% in Q1, so the story depends on cross-selling, pricing, and continued demand for new AI tools. Patient Payment Solutions, about 25% of revenue, faced headwinds from print-to-digital statement conversion and weather. If that volume-based revenue keeps weakening, the headline growth rate may look better than the core trend.
Paid when healthcare gets paid
Waystar makes money mainly from recurring subscription fees and volume-based fees. Subscription revenue is steadier. Volume-based revenue rises or falls with the number of claims, statements, or payment workflows that clients run through the platform.
The platform has a data flywheel. Each transaction gives Waystar more data about providers, patients, and payers. The company uses AI and rules-based software to improve automation, reduce errors, and help clients collect more of what they are owed.
Provider Solutions are the better-margin side of the house. Management said they are about 75% of revenue. Patient Payment Solutions are about 25% of revenue and have higher third-party costs, so a mix shift toward Provider Solutions helps margins.
Adjusted EBITDA was $135.4 million in Q1 2026, and management's thesis points to about a 43% adjusted EBITDA margin. The open question is whether Waystar can keep that margin while funding AI research, integrating Iodine, and defending price in a consolidated hospital market.
Claims, patients, and clinical AI
Provider Solutions
These tools help providers manage payer workflows, including claims, denials, and reimbursement tasks. They are about 75% of revenue and have better unit economics than patient payment tools.
Patient Payment Solutions
These products help providers collect money from patients through statements, payment tools, and engagement workflows. The segment is more exposed to transaction volumes and print-to-digital changes.
Clinical integrity and revenue capture
This solution set joins clinical and financial data to find coding mistakes, DRG underpayments, and missing charges. It aims to catch problems before they become denied or underpaid claims.
Iodine clinical intelligence
Iodine adds AI tools for clinical documentation, utilization management, and leakage prevention before billing. The deal expands Waystar deeper into the mid-cycle, where clinical records and payment rules meet.
Prebill anomaly detection
This AI capability looks for unusual issues before a bill goes out. It supports the broader goal of moving from manual repair work to prevention.
Altitude AI recoupment
This newer AI tool helps providers detect hidden payer recoupments, understand root causes, and act using remittance data at scale. Early adoption is an important test for the AI bookings story.
Two revenue pools
Waystar reports as one segment, but management discussed Q1 2026 revenue by solution type. Provider Solutions were about 75% of revenue, while Patient Payment Solutions were about 25%.
What could break the story
AI demand fades after early wins
High impact · Medium oddsAI-powered capabilities drove roughly 40% of new Q1 bookings, so investor expectations now lean on that trend. If new AI tools do not turn into durable revenue, the Iodine deal may look more like a costly add-on than a platform shift.
Patient payments volume pressure
Medium impact · Medium oddsPatient Payment Solutions are about 25% of revenue and carry higher third-party costs. Q1 had headwinds from print-to-digital statement conversion and weather, which showed how exposed this business can be to volume shifts.
NRR slips below the comfort zone
High impact · Medium oddsNet revenue retention was 110.5% for the 12 months ended March 31, 2026. That is healthy, but it has moved down from 113.1% at September 30, 2025 and 112.0% at December 31, 2025. A continued slide would weaken the case that Waystar can keep expanding inside its existing client base.
Iodine integration slows execution
Medium impact · Medium oddsWaystar bought Iodine for about $1.26 billion in 2025 to expand into AI-powered clinical intelligence. The strategy makes sense, but integration risk is real because the product set reaches deeper into clinical workflows.
Healthcare data and AI liability
High impact · Medium oddsWaystar handles sensitive healthcare data and operates under privacy and healthcare rules such as HIPAA. The company also warns that AI rules are changing and poor training data could create wrong outputs, unhappy clients, liability, or reputational harm.
In one breath
What does Waystar do?
Waystar sells cloud software for healthcare payments. Its platform helps providers submit claims, manage denials, improve billing, and collect from patients.
Why is Iodine important to Waystar?
Iodine adds AI-powered clinical intelligence. That helps Waystar find documentation and billing problems before claims are submitted, instead of only fixing payment issues later.
What is net revenue retention for Waystar?
Net revenue retention measures how much existing clients spend now compared with a prior period. Waystar reported 110.5% for the 12 months ended March 31, 2026.
What is the biggest risk for WAY stock?
The biggest business risk is that organic growth slows once acquisition help and temporary tailwinds fade. Investors should watch net revenue retention, AI bookings, and Patient Payment Solutions trends.